Peptides DB
Research-centric peptide and protocol reference hub
Study 18 of 18Zenagamtide literatureDiabetes, obesity & metabolism · ObservationalHigh-impact journal2026

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.

Zenagamtide's pharmacokinetics and safety profile appear unaffected by renal impairment, indicating no need for dose adjustments in this population.

Read at Diabetes, obesity & metabolismAdd to compare

Where it sits

this study against the rest of the zenagamtide corpus
4
Preclinical
9
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study measured the pharmacokinetics, safety, and tolerability of zenagamtide in adults with varying degrees of renal impairment compared to those with normal renal function. Participants received a single subcutaneous dose of 0.3 mg of zenagamtide, followed by a 4-week follow-up. The findings suggest that renal impairment does not significantly affect the pharmacokinetic properties or safety profile of zenagamtide.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
AUC0-∞ ranged from 520 to 715 h × nmol/L across renal impairment groups versus 543 h × nmol/L for the normal renal function group.2026

Abstract

The authors’ words, as Diabetes, obesity & metabolism supplied them

<h4>Aims</h4>Zenagamtide is a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal renal function.<h4>Materials and methods</h4>Adults with body mass index 20.0-39.9 kg/m<sup>2</sup> were categorised based on baseline renal status using the CKD-EPI Collaboration creatinine equation (2021); normal function, mild impairment, moderate impairment, severe impairment and end-stage renal disease (ESRD). Participants received a single subcutaneous dose of zenagamtide 0.3 mg, followed by a 4-week follow-up period. The primary endpoint was area under the zenagamtide plasma concentration-time curve from time zero to infinity (AUC<sub>0-∞</sub>). Additional endpoints included maximum observed plasma zenagamtide concentration (C <sub>max</sub>) and number of treatment-emergent adverse events (TEAEs).<h4>Results</h4>In total, 42 participants were included (n = 14, normal renal function group; n = 7 per renal impairment group). The range (geometric mean) of zenagamtide AUC<sub>0-∞</sub> and C <sub>max</sub> across renal impairment groups were 520-715 h × nmol/L and 2.8-3.5 nmol versus 543 h × nmol/L and 3.2 nmol/L for the normal renal function group, respectively. Overall, TEAEs were reported in 30 (71.4%) participants. TEAEs were non-serious, none were severe and the majority were mild and most frequently gastrointestinal in nature.<h4>Conclusions</h4>Renal impairment did not appear to have a clinically relevant impact on the PK or safety profile of zenagamtide, suggesting that dose adjustment of zenagamtide is not warranted in this population.<h4>Trial registration</h4>ClinicalTrials.gov: NCT06559527.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Zenagamtide corpus

CTargeting oxidative stress-NLRP3-apoptotic-steroidogenic axis in doxorubicin-induced testicular toxicity: protective efficacy of ferulic acid niosomes.Biological research · 2026 · n=40 · Not reported in abstract.AnimalCLymphatic Targeting of Flubendazole via Long-Chain Fatty Acid Nanoemulsion: Pharmacokinetic Evidence of Chylomicron-Mediated Uptake in Rats.ACS omega · 2026 · C_max = 2.42 ± 0.34 μg/mL for FLZ-NEAnimalDObstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis-Linked Remodeling.MedComm · 2026reviewBApplication of Clinical Indicators in the Early Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children: A Retrospective Study.Clinical pediatrics · 2026 · n=223 · The combined model's area under the curve was 0.946.HumanBRisk factors associated with malnutrition in elderly patients with chronic heart failure.Medicine · 2024 · n=203 · Area under the curve of 0.902 for the final model.HumanBSubfoveal Choroidal Thickness is Independently Associated with Axial Length and Myopia in Preschool Children: A Swept-Source Optical Coherence Tomography Study.Ophthalmology and therapy · 2026 · n=303 · Mean SFCT was 326.33 ± 43.01 μm in children aged 3-6 years.Human